GSK plc Q1 2026 Performance Update
GSK plc reported a strong Q1 2026 performance, with total sales reaching Β£7.6 billion, a 2% increase on a reported basis and 5% on a constant exchange rate (CER) basis. Specialty Medicines were a key driver, with sales up 14% (CER) to Β£3.2 billion, fueled by strong growth in HIV, Respiratory, Immunology & Inflammation, and Oncology. Vaccines sales increased by 4% (CER) to Β£2.1 billion, with Shingrix showing robust performance. General Medicines sales saw a 6% decline (CER) to Β£2.3 billion. The company reaffirms its 2026 guidance, expecting turnover growth of 3-5% and core operating profit growth of 7-9% (CER). GSK also highlighted significant progress in its R&D pipeline, with new product approvals and promising data readouts. The company also reaffirmed its 2031 sales outlook of over Β£40 billion.